GTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly ...

The regulator said the buyout “would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate ...

WASHINGTON (Reuters) - The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' ...

In the FTC’s first merger challenge of the new administration, the FTC voted 4-0 last week to challenge the proposed ...

Surmodics (NASDAQ:SRDX) fell 4.6% after the Federal Trade Commission filed a lawsuit to block its planned $627 million sale ...

Fintel reports that on March 7, 2025, Lake Street upgraded their outlook for Surmodics (NasdaqGS:SRDX) from Hold to Buy.

The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...

Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.

The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.

Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...

Lake Street Capital upgraded shares of Surmodics (NASDAQ:SRDX – Free Report) from a hold rating to a buy rating in a report published on Friday morning, Marketbeat.com reports. Lake Street Capital ...

The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq ...